Industries > Pharma > Translational Regenerative Medicine: Market Prospects 2016-2026

Translational Regenerative Medicine: Market Prospects 2016-2026

Can Promising Therapies in Stem Cells, Tissue Engineering and Gene Therapy Change the Way We Treat Rare and Chronic Diseases?

PUBLISHED: 29 January 2016
PAGES: 285
PRODUCT CODE: PHA0087
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0087 Categories: ,

What can be expected from the Translational Regenerative Medicine market? Which areas are going to grow at the fastest rates? This Visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.
 
Our 285-page report provides 170 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole of translational regenerative medicine market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications
How will submarkets perform to 2026? Our study forecasts revenues in the following Translational regenerative medicine submarkets:
• Stem Cell Therapies
• Tissue Engineering
• Gene Therapies

Translational Regenerative Medicine: Market Prospects 2016-2026

See revenue forecasts for some the leading products in the market
How will leading drug perform to 2026? Our study forecasts revenues for a number of leading products in the translational regenerative medicine market including:
• Osteocel Plus
• Trinity ELITE
• TEMCELL /Prochymal
• Apligraf
• Dermagraft
• ReCell
• Neovasculgen
• Glybera (alipogene tiparvovec)
• IMLYGIC (talimogene laherparepvec)

See revenue forecasts for the leading regional markets
How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets including products, including:
• US
• Europe
• Asia-Pacific
• Rest of World

Leading companies and potential for market growth
Overall revenue for the Translational Regenerative Medicine market will reach $12.1bn in 2020, our work forecasts. We predict strong revenue growth through to 2026. Advances in cellular and tissue research, an improving regulatory landscape, strong support from governments in multiple regions and the launch of several new therapies in areas of unmet clinical need will drive sales to 2026.

Our work analyses the key companies in the market. See Visiongain’s analysis of 16 leading companies, including these:
• Alphatec Spine
• Anterogen
• Athersys
• Avita Medical
• AxoGen
• Medipost
• Mesoblast
• NuVasive
• Ocata Therapeutics
• Organogenesis
• Osiris Therapeutics
• Pharmicell
• Regenersys
• TiGenix
• UniQure
• Vericel Corporation

A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Historic revenue, analysis and discussion of company performance over the past 5 years
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect translational regenerative medicine industry?
Our new report discusses issues and events affecting the translational regenerative medicine market. You will find discussions, including qualitative analyses:
• Highly diverse market needing strong knowledge of key therapeutic indications
• Changing regulatory landscape challenging new entrants and major market players alike
• Emerging therapies with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Translational Regenerative Medicine: Market Prospects 2016-2026 report helps you
In summary, our 285-page report gives you the following knowledge:
• Revenue forecasts to 2026 for the Translational Regenerative Medicine market – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2026 for each major submarket – discover prospects for leading translational regenerative medicine products in the following areas: stem cell therapies, tissue engineering and gene therapy.
• Revenue forecasts to 2026 for 9 of the leading products in the Translational Regenerative Medicine market – discover prospects for leading translational regenerative medicine products including: Osteocel Plus, Trinity ELITE, TEMCELL /Prochymal, Apligraf, Dermagraft, ReCell, Neovasculgen, Glybera (alipogene tiparvovec) and IMLYGIC (talimogene laherparepvec)
• Revenue forecasts to 2026 for one leading national market and two leading regional markets – US, Europe, Asia-Pacific and Rest of World
• Assessment of 16 leading companies – analysis of products, revenue, mergers & acquisitions, sales by region, therapeutic area and product type
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the translational regenerative medicine market and leading companies. You will find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Translational Regenerative Medicine: Market Prospects 2016-2026


Download sample pages

Complete the form below to download your free sample pages for Translational Regenerative Medicine: Market Prospects 2016-2026


Latest Pharma news

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

READ

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

READ

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

READ

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

READ

Categories

Category